Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

• Published in: NPJ precision oncology Vol. 5; no. 1; pp. 30 - 13
• Main Authors: Wensink, G. Emerens, Elias, Sjoerd G., Mullenders, Jasper, Koopman, Miriam, Boj, Sylvia F., Kranenburg, Onno W., Roodhart, Jeanine M. L.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 12-04-2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/53/2423; 692/308/575; 692/4028/67/1059; Biomarkers; Cancer; Cancer Research; Gene Therapy; Human Genetics; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Patients; Precision medicine; Review; Review Article; Targeted cancer therapy
• ISSN: 2397-768X; 2397-768X
• DOI: 10.1038/s41698-021-00168-1

Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.